Silence Therapeutics Plc ADR [NASDAQ: SLN] stock went on a downward path that fall over -36.75% on Thursday, amounting to a one-week price decrease of less than -57.00%.
Over the last 12 months, SLN stock dropped by -23.41%. The one-year Silence Therapeutics Plc ADR stock forecast points to a potential upside of 87.26. The average equity rating for SLN stock is currently 1.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $329.05 million, with 39.62 million shares outstanding and 37.55 million shares in the current float. Compared to the average trading volume of 185.60K shares, SLN stock reached a trading volume of 4499988 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Silence Therapeutics Plc ADR [SLN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SLN shares is $54.70 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SLN stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Silence Therapeutics Plc ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 03, 2024. While these analysts kept the previous recommendation, BMO Capital Markets raised their target price to Outperform. The new note on the price target was released on January 31, 2024, representing the official price target for Silence Therapeutics Plc ADR stock.
The Average True Range (ATR) for Silence Therapeutics Plc ADR is set at 1.28, with the Price to Sales ratio for SLN stock in the period of the last 12 months amounting to 16.00. The Price to Book ratio for the last quarter was 2.60, with the Price to Cash per share for the same quarter was set at 3.66.
SLN Stock Performance Analysis:
Silence Therapeutics Plc ADR [SLN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -57.00. With this latest performance, SLN shares dropped by -61.21% in over the last four-week period, additionally sinking by -70.85% over the last 6 months – not to mention a drop of -23.41% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SLN stock in for the last two-week period is set at 7.83, with the RSI for the last a single of trading hit 3.99, and the three-weeks RSI is set at 12.39 for Silence Therapeutics Plc ADR [SLN]. The present Moving Average for the last 50 days of trading for this stock 17.58, while it was recorded at 11.98 for the last single week of trading, and 20.12 for the last 200 days.
Insight into Silence Therapeutics Plc ADR Fundamentals:
Silence Therapeutics Plc ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.31 and a Current Ratio set at 9.31.
SLN Stock EPS
With the latest financial reports released by the company, Silence Therapeutics Plc ADR posted -0.48/share EPS, while the average EPS was predicted by analysts to be reported at -0.21/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.27. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SLN.
Silence Therapeutics Plc ADR [SLN] Institutonal Ownership Details
There are presently around $62.77%, or 75.57%% of SLN stock, in the hands of institutional investors. The top three institutional holders of SLN stocks are: TCG CROSSOVER MANAGEMENT, LLC with ownership of 3.3 million shares, which is approximately 7.4962%. ARTAL GROUP S.A., holding 2.78 million shares of the stock with an approximate value of $$52.81 million in SLN stocks shares; and ARTAL GROUP S.A., currently with $$36.76 million in SLN stock with ownership which is approximately 5.4731%.
